- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01829282
Eban II: Intervention for HIV Sero-Discordant Couples
Implementing Eban II: An Evidence-Based Intervention for HIV Sero-Discordant Couples
This study focuses on the implementation of an evidence-based HIV risk reduction intervention for HIV-serodiscordant, heterosexual African American couples ("Eban II") in two geographic areas (Northern and Southern California - roughly, Alameda and Los Angeles Counties) that have a high prevalence of HIV infection and risk conditions among African Americans.
The Specific Aims are as follows:
- To evaluate implementation of Eban for HIV serodiscordant African American couples in 10 CBOs in California. To do this, we will document the implementation process and identify barriers and facilitators to Eban's adoption and use by the CBOs. We will interview 200 staff at CBOs to obtain this information.
- To evaluate the effect of Eban on behavioral and biological outcomes among 180 couples, specifically incidents of protected sex, proportion of condom use, and incident sexually transmitted infections. Eban will be assessed using a randomized delayed enrollment (waitlist) control design to evaluate the impact of treatment on outcomes at posttest and 3-month follow-up (i.e., at these 10 CBOs, Eban will be conducted and offered to couples and evaluated for effectiveness - that is, how well it works in the real world.)
- To determine the cost-effectiveness of implementation of Eban, based on implementation costs and potential cost savings.
Study Overview
Status
Intervention / Treatment
Detailed Description
The HIV/AIDS epidemic continues to disproportionately affect African Americans. The rate of HIV among African American men is six times the rate for White men and the rate among African American women is almost 15 times the rate for White women. An estimated 56,300 new HIV cases was reported in 2006, of which 49% were among African Americans and 80% were from heterosexual transmission. Sexually transmitted infections (STIs) also disproportionately affect African Americans, further increasing the risk for HIV transmission. Despite the fact that HIV and STIs are primarily transmitted in the context of relationships, few interventions address HIV risk in couples. Furthermore, few evidence-based HIV prevention interventions have been implemented in community-based organizations (CBOs). Thus, there is a substantial need to strengthen the availability and use of relationship oriented prevention interventions in community-based treatment settings.
This study focuses on the implementation of an evidence-based HIV risk reduction intervention for HIV-serodiscordant, heterosexual African American couples ("Eban II") in two geographic areas (Northern and Southern California - roughly, Alameda and Los Angeles Counties) that have a high prevalence of HIV infection and risk conditions among African Americans.
This study builds upon the multi-site, NIMH-funded "Eban" (a Yoruba term for "fence") trial, which tested this culturally congruent intervention versus a control condition among 535 heterosexual HIV serodiscordant couples in four cities. Couples in the intervention had significantly reduced incidents of unprotected sex and an increased proportion of condom use compared to couples in the control condition. Statistical projections from that study suggest that if Eban participants had not received the intervention, six female and four males would have been infected in one year, and 25 females and 15 males would have become HIV-infected in the next 5 years. Based on these successful outcomes in a controlled trial, it is now appropriate to test the effectiveness of the intervention as delivered in community-based setting. Thus, we propose to conduct a study of implementation - a study of methods to promote the uptake of Eban into community-based organizations (CBOs).
The Specific Aims are as follows:
- To evaluate implementation of Eban for HIV serodiscordant African American couples in 10 CBOs in California. To do this, we will document the implementation process and identify barriers and facilitators to Eban's adoption and use by the CBOs. We will interview 200 staff at CBOs to obtain this information.
- To evaluate the effect of Eban on behavioral and biological outcomes among 180 couples, specifically incidents of protected sex, proportion of condom use, and incident sexually transmitted infections. Eban will be assessed using a randomized delayed enrollment (waitlist) control design to evaluate the impact of treatment on outcomes at posttest and 3-month follow-up (i.e., at these 10 CBOs, Eban will be conducted and offered to couples and evaluated for effectiveness - that is, how well it works in the real world.)
- To determine the cost-effectiveness of implementation of Eban, based on implementation costs and potential cost savings.
So please note, there are essentially two levels to this study -- first to see how well community agencies can implement or take up and execute the intervention (thus, the interviews with staff) - and the second, to see how effective Eban is in real world setting. We know it was highly effective in a controlled study but now we need to test how well it works in the "real" world(thus, the testing of the intervention with 180 couples). While doing this, we will also be examining the cost-effectiveness of the intervention in the "real" world setting.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Alicia M Eccles, MPH
Study Locations
-
-
California
-
Long Beach, California, United States, 90806
- Not yet recruiting
- Tarzana Treatment Centers
-
Los Angeles, California, United States, 90005
- Not yet recruiting
- AIDS Project Los Angeles
-
Los Angeles, California, United States, 90015
- Not yet recruiting
- AIDS Healthcare Foundation
-
Los Angeles, California, United States, 90059
- Not yet recruiting
- O.A.S.I.S. Clinic
-
Oakland, California, United States, 94601
- Recruiting
- HIV Education & Prevention Project of Alameda County
-
Contact:
- Melissa Struzzo, MPH
- Email: mstruzzo@casasegura.org
-
Oakland, California, United States, 94608
- Not yet recruiting
- CAL-PEP
-
Oakland, California, United States, 94612
- Not yet recruiting
- Allen Temple
-
Oakland, California, United States, 94612
- Not yet recruiting
- Women Organized to Respond to Life-Threatening Disease
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Must be in a relationship with study partner for at least 3 months
- Both partners must be 18 years or older
- At least one partner must identify as African American/Black
- One partner must be HIV positive and one partner must be HIV negative
- Must be a heterosexual couple (one biological female and one biological man)
- Not currently expecting a child and not planning on having children within the year.
Exclusion Criteria:
- Less than 18 years old
- No partner
- Couple is not heterosexual
- Insufficient relationship length/commitment
- No reported incidents of unprotected intercourse in the past 90 days
- Neither partner is African American/Black
- One/both partners unaware of others HIV status
- Couple is not serodiscordant
- One/both partners reported partner violence
- HIV diagnosis received recently (less than 3 months)
- One/both partners participated in a HIV Risk Reduction study within the past 12 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Risk Reduction
The Risk Reduction group will receive the Eban II Intervention upon enrollment. This group will do the following:
|
|
Active Comparator: Waitlist
The Waitlist group will receive the same intervention after waiting for the Risk Reduction group to complete the entire intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safe Sex
Time Frame: within 3 months of completion of the intervention
|
Proportion of unprotected acts of sex.
|
within 3 months of completion of the intervention
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Gail E Wyatt, PhD, University of California, Los Angeles
- Study Director: John Williams, MD, University of California, Los Angeles
- Study Director: Brian Mittman, PhD, VA Office of Research and Development
- Study Director: Alison Hamilton, PhD, University of California, Los Angeles
- Study Director: Hector Myers, PhD, University of California, Los Angeles
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3294930
- R01MH093230-01 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sexually Transmitted Diseases
-
Columbia UniversityNational Institute of Allergy and Infectious Diseases (NIAID)RecruitingSTI | Sexually Transmitted Disease (STD) | Sexually Transmitted Infection (STI)United States
-
National Institute of Allergy and Infectious Diseases...Terminated
-
Boston Medical CenterCompletedSexually Transmitted InfectionUnited States
-
University of ChicagoCompletedSexually Transmitted InfectionUnited States
-
University of California, San FranciscoNational Institute of Mental Health (NIMH); MRC/UVRI and LSHTM Uganda Research... and other collaboratorsCompletedSexually Transmitted InfectionUganda
-
Assistance Publique Hopitaux De MarseilleCompletedSexually Transmitted InfectionFrance
-
University of Illinois at ChicagoEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedHiv | Sexually Transmitted InfectionSouth Africa
-
Boston Medical CenterCompletedSexually Transmitted InfectionUnited States
-
Chinese University of Hong KongRecruitingGonorrhea | Sexually Transmitted InfectionHong Kong
-
Sagami Rubber Industries Co., Ltd.Essential Access HealthCompletedContraception | Prevention of Sexually Transmitted InfectionsUnited States
Clinical Trials on Risk Reduction
-
Columbia UniversityNational Institute of Mental Health (NIMH)Completed
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Diseases | Cardiovascular Diseases | Coronary Disease | Risk Reduction
-
University of New MexicoNational Institute on Alcohol Abuse and Alcoholism (NIAAA)WithdrawnDrinking Behavior | Sexual Behavior | Health Behavior | Adolescent Behavior | Risk Reduction BehaviorUnited States
-
University of PennsylvaniaNational Institute on Minority Health and Health Disparities (NIMHD)CompletedHuman Immunodeficiency Virus (HIV) | Sexually Transmitted Disease (STD)United States
-
Northwell HealthActive, not recruitingCoronary Artery Disease | Atherosclerotic Cardiovascular DiseaseUnited States
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)CompletedSubstance Use Disorders | Risk ReductionUnited States
-
Florida State UniversityUnited States Department of DefenseCompleted
-
University of Alabama at BirminghamEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingMaternal Cytomegalovirus Infections | Cytomegalovirus CongenitalUnited States
-
University of Maryland, College ParkCompleted